Hepatorenal syndrome

Southern Medical Journal

Volumn 103, Issue 7, 2010, Pages 654-659

  Venkat, Deepak ^a   Venkat, K K ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b NONE

Author keywords

Acute kidney injury; end stage liver disease; hepatorenal syndrome

Indexed keywords

ALBUMIN; CEPHALOSPORIN; MIDODRINE; NORADRENALIN; OCTREOTIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; TERLIPRESSIN;

ANTIBIOTIC THERAPY; BACTERIAL PERITONITIS; CONTINUOUS INFUSION; DIAGNOSTIC APPROACH ROUTE; DRUG DOSE INCREASE; HEPATORENAL SYNDROME; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY INJURY; LIVER TRANSPLANTATION; PATHOGENESIS; RENAL REPLACEMENT THERAPY; REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VASOCONSTRICTION;

ANTI-BACTERIAL AGENTS; HEPATORENAL SYNDROME; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; PROGNOSIS; RENAL REPLACEMENT THERAPY; VASOCONSTRICTOR AGENTS;

EID: 77954244970     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181e07751     Document Type: Review

References (36)

1. Wadei HM, Mai ML, Ahsan N, et al. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006;1:1066-1079.
2. Ginès P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet 2003;362:1819-1827.
3. Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007;46:935-946.
4. Koppel M, Coburn JW, Mims MM, et al. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome: evidence for functional nature of renal failure in advanced liver disease. N Engl J Med 1969;280:1367-1371.
5. Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-176.
6. Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome with cirrhosis. Gut 2007;56:1310-1318. (Pubitemid 47300435)
7. Mackelaite L, Alsauskas ZC, Ranganna K. Renal failure in patients with cirrhosis. Med Clin North Am 2009;93:855- 869, viii.
8. MacAulay J, Thompson K, Kiberd BA, et al. Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction: are the equations for estimating renal function better? Can J Gastroenterol 2006;20:521-526.
9. Proulx NL, Akbari A, Garg AX, et al. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol Dial Transplant 2005;20:1617-1622.
10. Daugherty NA, Hammond KB, Osberg IM. Bilirubin interference with the kinetic Jaffé method for serum creatinine. Clin Chem 1978;24:392-393.
11. Ginés A, Escorsell A, Ginés P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
12. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves shortterm survival in severe acute alcoholic hepatitis: a double-blind, placebo- controlled trial. Gastroenterology 2000;119:1637-1648.
13. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;35:1179-1185. (Pubitemid 34454015)
14. Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 1991;51:428-430.
15. Arroyo V, Fernandez J, Ginés P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008;28:81-95.
16. Niederberger M, Martin PY, Ginès P, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995;109:1624-1630.
17. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422-433.
18. Ginés P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361:1279-1290.
19. Asbert M, Ginés A, Ginés P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993;104:1485-1491.
20. Bories PN, Campillo B, Azaou L, et al. Long-lasting NO overproduction in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1997;25:1328-1333.
21. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-1501.
22. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.
23. Bailey J, Shapiro MJ. Abdominal compartment syndrome. Crit Care 2000;4:23-29.
24. de Cleva R, Silva FP, Zilberstein B, et al. Acute renal failure due to abdominal compartment syndrome: report on four cases and literature review. Rev Hosp Clin Fac Med Sao Paulo 2001;56:123-130.
25. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-824.
26. Sandhu BS, Sanyal AJ. Management of ascites in cirrhosis. Clin Liver Dis 2005;9:715-732, viii.
27. Ginés A, Salmeron JM, Ginés P, et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 1993;17:220-226.
28. Wong F, Moore K, Dingemanse J, et al. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type-2 hepatorenal syndrome. Hepatology 2008;47:160-168.
29. Saló J, Ginés A, Quer JC, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996;25:916-923.
30. Fernández J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005;42:627-634.
31. Pomier-Layrargues G, Paquin SC, Hassoun Z, et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38:238-243.
32. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-1368.
33. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-1697.
34. Sharma P, Kumar A, Sharma BC, et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastrenterol 2008;103:1689-1697.
35. Martín-Llahí M, Pépin MN, Guevara M, et al; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-1359.
36. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47: 288-295.